Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Combination Therapy
100%
B-CLL
100%
Prognostic Factors
100%
B Cells
100%
Bevacizumab
66%
Rituximab
66%
Monoclonal Antibody
66%
Cyclophosphamide
66%
Clinical Outcomes
66%
Previously Untreated
66%
CLL Patients
66%
Clinical Response
66%
Anti-VEGF Therapy
66%
Pentostatin
66%
Improved Survival
33%
Elderly Patients
33%
Minimal Residual Disease
33%
Clinical Efficacy
33%
Disease Outcome
33%
Patient Will
33%
Site Familiarity
33%
Therapeutic Regimen
33%
Paracrine
33%
Computed Tomography
33%
Flow Cytometry
33%
Progressive Disease
33%
Disease Response
33%
Combination Chemotherapy
33%
Imaging Studies
33%
Independent Prognostic Factor
33%
Disease Survival
33%
Low Incidence
33%
Optimal Drug Delivery
33%
Chronic Lymphocytic Leukemia
33%
Poor Performance Status
33%
Performance Status
33%
% Response
33%
Residual Disease
33%
Spleen Size
33%
Avastin
33%
Node Size
33%
High Risk
33%
Progression-free
33%
Quality of Life
33%
Mechanism of Action
33%
Treatment Enhancement
33%
Disease Prediction
33%
High-risk Disease
33%
Enhanced Quality
33%
Survival Time
33%
Angiogenesis
33%
Level of Response
33%
Risk Stratification
33%
Survival Pathways
33%
Risk Factors
33%
Prognostic Model
33%
Marrow Suppression
33%
Creatinine Clearance
33%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
33%
Non-overlapping
33%
Malignancy
33%
Tumor Vasculature
33%
Stratification Parameter
33%
Risk Disease
33%
Drug Antibodies
33%
Combined Method
33%
Well Tolerated
33%
Leukemia
33%
Surrogate Marker
33%
Major Infections
33%
Drug Combination
33%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Diseases
100%
Chronic Lymphatic Leukemia
100%
Vasculotropin
80%
Bevacizumab
60%
Pentostatin
40%
Minimal Residual Disease
40%
Monoclonal Antibody
40%
Rituximab
40%
Cyclophosphamide
40%
Drug Antibody
20%
Flow Cytometry
20%
Leukemia
20%
Progression Free Survival
20%
Tumor Vascularization
20%
Chemotherapy Regimens
20%
Creatinine
20%
Disease Marker
20%
Infection
20%
Survival Time
20%
Immunology and Microbiology
Vasculotropin
100%
B Cell
75%
Bevacizumab
75%
Cyclophosphamide
50%
Monoclonal Antibody
50%
Rituximab
50%
Infectious Disease
25%
Progression Free Survival
25%
Prognostic Model
25%
Infection
25%
Spleen Size
25%
Tumor Vascularization
25%
Angiogenesis
25%
In Vitro
25%
Survival Time
25%
Drug Antibody
25%
X-Ray Computed Tomography
25%
Creatinine Clearance
25%